Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,947 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $69.28, for a total transaction of $550,568.16. Following the transaction, the insider owned 32,718 shares of the company’s stock, valued at $2,266,703.04. The trade was a 19.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Joana Goncalves also recently made the following trade(s):

• On Friday, May 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $61.85, for a total transaction of $432,950.00.
• On Wednesday, April 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $66.12, for a total transaction of $462,840.00.

Oruka Therapeutics Stock Performance

Shares of ORKA traded down $1.03 on Monday, hitting $68.86. 1,002,319 shares of the stock traded hands, compared to its average volume of 1,071,721. The company has a market capitalization of $4.15 billion, a PE ratio of -35.49 and a beta of -0.25. The business has a 50 day simple moving average of $63.40 and a 200 day simple moving average of $44.04. Oruka Therapeutics, Inc. has a one year low of $10.77 and a one year high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.04. On average, equities analysts expect that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. UBS Group raised their price target on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Wedbush set a $165.00 price target on shares of Oruka Therapeutics in a research report on Monday, April 27th. BTIG Research reissued a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a research report on Thursday, May 14th. Guggenheim set a $200.00 target price on shares of Oruka Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 27th. Finally, Leerink Partners set a $120.00 target price on shares of Oruka Therapeutics in a research report on Thursday, April 30th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $131.30.

Hedge Funds Weigh In On Oruka Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada grew its holdings in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after purchasing an additional 365 shares during the period. Kennedy Capital Management LLC lifted its position in shares of Oruka Therapeutics by 0.9% during the 4th quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after buying an additional 420 shares in the last quarter. AlphaCentric Advisors LLC lifted its position in shares of Oruka Therapeutics by 5.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after buying an additional 626 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Oruka Therapeutics by 35.0% during the 4th quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after acquiring an additional 788 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Oruka Therapeutics by 62.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock valued at $71,000 after acquiring an additional 904 shares during the period. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.